Gilead Maps Out Cellular Therapy Strategy With Kite Acquisition

Gilead Sciences has made one of its largest deals to date with its nearly $11 billion Kite Pharma acquisition, a deal that reflects a major push into cellular therapy for the pharma company. Executives highlighted their thinking behind the deal on a conference call with analysts.